The end of an era: shall we move forward?
- PMID: 21911728
- DOI: 10.1200/JCO.2011.36.7417
The end of an era: shall we move forward?
Comment on
-
Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial.J Clin Oncol. 2011 Oct 10;29(29):3877-84. doi: 10.1200/JCO.2010.28.5437. Epub 2011 Sep 12. J Clin Oncol. 2011. PMID: 21911726 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical